

Mirati Therapeutics, Inc.  
Form 8-K  
January 24, 2018

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 18, 2018

Mirati Therapeutics, Inc.  
(Exact name of registrant as specified in its charter)

Delaware                      001-35921                      46-2693615  
(State of incorporation) (Commission File No.) (IRS Employer Identification No.)

9393 Towne Centre Drive, Suite 200  
San Diego, California 92121  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (858) 332-3410

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: Mirati Therapeutics, Inc. - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 18, 2018, our Compensation Committee approved 2017 incentive cash bonus payments to our executive officers. The bonus payments were based on an assessment of the achievement of corporate goals set out and approved by the Board of Directors in 2017. The 2017 cash bonuses approved for each of our named executive officers and principal financial officer were as follows:

Name	Title	2017 Cash Bonus
Charles M. Baum, M.D., Ph.D.	President and Chief Executive Officer	\$225,100
Isan Chen, M.D.	Executive Vice President and Chief Medical and Development Officer	\$130,700
James Christensen, Ph.D.	Senior Vice President and Chief Scientific Officer	\$115,400
Jamie A. Donadio	Senior Vice President and Chief Financial Officer	\$105,600

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 24, 2018  
Mirati Therapeutics, Inc.

By: /s/ Jamie A. Donadio

Jamie A. Donadio

Senior Vice President and Chief Financial Officer